Novel Myelofibrosis Drug is “Versatile” for Managing Anemia

Rákkutatás · Myelofibrosis

DISC‑0974 showed meaningful hemoglobin increases in both patients with JAK‑inhibitor‑treated and untreated myelofibrosis with anemia.

Investigational anti‑hemokuvelin monoclonal antibody DISC‑0974 demonstrated clinically meaningful hemoglobin increases in patients with myelofibrosis–related anemia, irrespective of prior JAK‑inhibitor exposure (phase 2 RALLY‑MF).

The ability to raise hemoglobin in both JAK‑inhibitor‑treated and untreated patients indicates that DISC‑0974 can be used as a monotherapy or combined with existing JAK‑inhibitors, potentially enabling patients to stay on their current therapy longer and improving anemia management in myelofibrosis.

Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.

Eredeti forrás

Kapcsolódó jelek